Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Current Liabilities for the year ending March 31, 2024: USD 9.22 M

Supriya Lifescience Limited Current Liabilities is USD 9.22 M for the year ending March 31, 2024, a -20.89% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Supriya Lifescience Limited Current Liabilities for the year ending March 31, 2023 was USD 11.65 M, a -11.25% change year over year.
Supriya Lifescience Limited Current Liabilities for the year ending March 31, 2022 was USD 13.13 M, a -34.16% change year over year.
Supriya Lifescience Limited Current Liabilities for the year ending March 31, 2021 was USD 19.94 M, a -3.29% change year over year.
Supriya Lifescience Limited Current Liabilities for the year ending March 31, 2020 was USD 20.62 M, a 6.22% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Tobacco

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years